New Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review.

Cancers (Basel) · 2025 · PMC12691000 · PMID 41375037

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although pasireotide LAR showed a trend toward higher tumor control rates at six months, this was not statistically significant [ 82 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.